Therefore, the present invention further relates to a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, and use of the pharmaceutical composition in the preparation of drugs. The drugs are used for improving the activity of immune cells and enhancing the immune...
BACKGROUND: Non-steroidal anti-inflammatory drugs (NSAIDs) may increase blood pressure (BP) and blunt the effects of many antihypertensives. It seems that ... Ivancica Pavlicevi,Marion Kuzmani,M Rumboldt,... - 《Journal Canadien De Pharmacologie Clinique》 被引量: 91发表: 2008年 ...
43,44,45,46], targeting the LAG3-specific inhibitory pathway may enhance anti-MM immunity and have a more favorable therapeutic index. Importantly, among the clinical grade checkpoint inhibitors and immune agonists evaluated in these studies, anti-LAG3 treatment significantly...
In the past decade, great strides have been made in cancer therapy with the ascendancy of immune checkpoint inhibitors (CPIs). These drugs work by using blocking antibodies to disrupt the inhibitory signaling of immune checkpoint proteins that reside on the surface of lymphocytes such as T cells ...
Therefore, the present invention further relates to a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, and use of the pharmaceutical composition in the preparation of drugs. The drugs are used for improving the activity of immune cells and enhancing the immune...
The secondary endpoints include efficacy (overall survival, DMFS, melanoma-specific survival), safety [treatment-emergent adverse events (TEAEs), interruption or discontinuation of drugs due to TEAEs], pharmacokinetic (concentrations of fianlimab and cemiplimab in serum over time), immunogenicity (anti...
Patients will receive anti-PD-1 q4w and anti-TIM-3 and LAG-3 q2w for up to 24 weeks (Induction Phase) followed by all drugs q6w (Maintenance Phase). Treatment will end 2 years after starting the study drugs, or upon disease progression, unacceptable toxicity, or study withdrawal. ...
Further provided are a nucleotide molecule for encoding the antibody, an expression vector and a host cell for expressing the antibody, a composition containing the antibody, and the use of the antibody in the preparation of drugs for resisting tumors, treating autoimmune diseases, and treating ...
It also provides procedures for the manufacture of Drugs useful for Treatment or prevention of cancer or infection using such compositions.In addition, the methods of expression of recombinant Antibodies and Fragments are part of the present Invention.GOPALAN RAGHUNATHAN...